Can a Pre-Surgery drug wake up the immune system against breast cancer?

NCT ID NCT04891068

Recruiting now Knowledge-focused Sponsor: University of Illinois at Chicago Source: ClinicalTrials.gov ↗

First seen Jan 18, 2026 · Last updated May 20, 2026 · Updated 22 times

Summary

This study is for people with high-risk early-stage breast cancer. It tests whether taking a low dose of the drug azacitidine before surgery can increase immune cells inside the tumor. The goal is to see if this approach can make the body's own defenses fight the cancer more effectively. About 40 participants will receive the drug and then have their tumors measured before and after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY STAGE BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Illinois Cancer Center
RECRUITING

Chicago, Illinois, 60612, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

BREAST CANCER INVASIVE EARLY STAGE BREAST CANCER HIGH RISK BREAST CARCINOMA